Ornithine Transcarbamylase (OTC) Deficiency
Neurology·MeSH: Ornithine Carbamoyltransferase Deficiency Disease
Prevalence
5.0 / 100K
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| ecur-506 | PRECISION BIOSCIENCES INC (DTIL) |
Frequently asked questions
How many drugs are in development for Ornithine Transcarbamylase (OTC) Deficiency?
BioSniper tracks 1 drug in development for Ornithine Transcarbamylase (OTC) Deficiency across 1 company.
How many clinical trials target Ornithine Transcarbamylase (OTC) Deficiency?
There are 1 clinical trial targeting Ornithine Transcarbamylase (OTC) Deficiency tracked by BioSniper.
What is the prevalence of Ornithine Transcarbamylase (OTC) Deficiency?
The estimated prevalence of Ornithine Transcarbamylase (OTC) Deficiency is approximately 5.0 per 100,000 population.
Deep-dive into Ornithine Transcarbamylase (OTC) Deficiency
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis